MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
14.04
-0.06
-0.43%
After Hours: 14.04 0 0.00% 16:10 12/18 EST
OPEN
14.18
PREV CLOSE
14.10
HIGH
14.40
LOW
13.80
VOLUME
4.49M
TURNOVER
--
52 WEEK HIGH
63.00
52 WEEK LOW
13.80
MARKET CAP
844.48M
P/E (TTM)
-8.3821
1D
5D
1M
3M
1Y
5Y
1D
Janux Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 1d ago
Janux Therapeutics Price Target Cut to $29.00/Share From $48.00 by Barclays
Dow Jones · 1d ago
Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29
Benzinga · 1d ago
Janux Therapeutics price target lowered to $29 from $48 at Barclays
TipRanks · 1d ago
JANUX THERAPEUTICS <JANX.O>: BARCLAYS CUTS TARGET PRICE TO $29 FROM $48
Reuters · 1d ago
Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks · 1d ago
50 heavily shorted laggards poised to rebound according to Wells Fargo
Seeking Alpha · 2d ago
Weekly Report: what happened at JANX last week (1208-1212)?
Weekly Report · 3d ago
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.